Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice

Clinical and Experimental Immunology

Volumn 155, Issue 2, 2009, Pages 339-347

  Paixao Cavalcante D ^a   Botto, M ^a   Cook, H T ^a   Pickering, M C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Complement; Thrombosis; Toxin

Indexed keywords

COMPLEMENT FACTOR H; LIPOPOLYSACCHARIDE; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GLOMERULUS; HEMOLYTIC UREMIC SYNDROME; HISTOLOGY; HOST SUSCEPTIBILITY; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY TUBULE DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA; WILD TYPE;

ANIMALS; APOPTOSIS; COMPLEMENT FACTOR H; FEMALE; HEMOLYSIS; HEMOLYTIC-UREMIC SYNDROME; KIDNEY GLOMERULUS; KIDNEY TUBULES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; SHIGA TOXIN 2; SPLEEN; UREMIA;

EID: 58149314122     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03826.x     Document Type: Article

References (35)

1. Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am 2003 17 : 177 99.
2. Moake JL. Haemolytic-uraemic syndrome: basic science. Lancet 1994 343 : 393 7.
3. Kulzer P, Wanner C. Thrombotic microangiopathy: a challenge with uncertain outcome. Nephrol Dial Transpl 1998 13 : 2154 60.
4. Le Saux N, Spika JS, Friesen B et al. Ground beef consumption in noncommercial settings is a risk factor for sporadic Escherichia coli O157:H7 infection in Canada. J Infect Dis 1993 167 : 500 2.
5. Carter AO, Borczyk AA, Carlson JA et al. A severe outbreak of Escherichia coli O157:H7 - associated hemorrhagic colitis in a nursing home. N Engl J Med 1987 317 : 1496 500.
6. Sandvig K, Dubinina E, Garred O et al. Protein toxins: mode of action and cell entry. Biochem Soc Trans 1992 20 : 724 7.
7. Lingwood CA. Verotoxin-binding in human renal sections. Nephron 1994 66 : 21 8.
8. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 2001 16 : 823 39.
9. Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002 126 : 1430 3.
10. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC) - associated hemolytic-uremic syndrome. Semin Thromb Hemost 2001 27 : 207 13.
11. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001 60 : 831 46.
12. Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 2007 16 : 565 71.
13. Esparza-Gordillo J, Jorge EG, Garrido CA et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006 43 : 1769 75.
14. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006 108 : 1267 79.
15. Fang CJ, Fremeaux-Bacchi V, Liszewski MK et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008 111 : 624 32.
16. Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008 151 : 210 30.
17. Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002 31 : 424 8.
18. Wadolkowski EA, Sung LM, Burris JA et al. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 1990 58 : 3959 65.
19. Barrett TJ, Potter ME, Wachsmuth IK. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun 1989 57 : 3434 7.
20. Palermo MS, Alves Rosa MF, Van Rooijen N et al. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Clin Exp Immunol 1999 116 : 462 7.
21. Palermo M, Alves-Rosa F, Rubel C et al. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol 2000 119 : 77 83.
22. Rutjes NW, Binnington BA, Smith CR et al. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 2002 62 : 832 45.
23. Tesh VL, Burris JA, Owens JW et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 1993 61 : 3392 402.
24. Motto DG, Chauhan AK, Zhu G et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005 115 : 2752 61.
25. Ikeda M, Ito S, Honda M. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Pediatr Nephrol 2004 19 : 485 9.
26. Roche JK, Keepers TR, Gross LK et al. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation. Am J Pathol 2007 170 : 526 37.
27. Keepers TR, Psotka MA, Gross LK et al. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006 17 : 3404 14.
28. Robson MG, Cook HT, Botto M et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001 166 : 6820 8.
29. Karpman D, Connell H, Svensson M et al. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997 175 : 611 20.
30. Wadolkowski EA, Burris JA, O'Brien AD. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 1990 58 : 2438 45.
31. Harel Y, Silva M, Giroir B et al. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 1993 92 : 2110 16.
32. Wolski VM, Soltyk AM, Brunton JL. Tumour necrosis factor alpha is not an essential component of verotoxin 1-induced toxicity in mice. Microb Pathog 2002 32 : 263 71.
33. Dran GI, Fernandez GC, Rubel CJ et al. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int 2002 62 : 1338 48.
34. Morigi M, Buelli S, Zanchi C et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006 169 : 1965 75.
35. Liu XH, Lingwood CA, Ray PE. Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease. Kidney Int 1999 55 : 554 61.